Novo Nordisk has acknowledged that the first phase 3 readout for new obesity hopeful CagriSema was hard to interpret and disappointed investors, but it has a plan to revitalise the programme.

The stock is up 8.55% over the last year and 7.45% year-to-date. Let’s look at what the charts indicate for Novo Nordisk stock and how the stock maps against Wall Street estimates. Novo Nordisk ...

Novo Nordisk shares have dropped significantly in ... dip in NVO stock that didn't prove to be a buying opportunity? The chart below says "No." That's likely because the company keeps growing ...

The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Novo Nordisk. The chart below ...

Novo Nordisk is trading almost at par with the industry, as seen in the chart below. Going by the price/earnings ratio, the company’s shares currently trade at 15.13 forward earnings ...

Novo Nordisk has underperformed the broad market on the price charts over the past 12 months, down 17% vs the S&P 500's 27% gain. But Wall Street remains bullish on the healthcare stock.

Novo Nordisk A/S (NVO) investors have suffered a rare bear market since the stock topped out in June 2024. As a result, the market seems primed for increasing headwinds against NVO's heightened ...

Novo Nordisk's (NVO) investors are worried its competition with Eli Lilly (LLY) is heating up and that the first-to-market GLP-1 leader is losing ground. Even with 72% of the global market share ...

LONDON/COPENHAGEN (Reuters) -Obesity drug maker Novo Nordisk (NVO) forecast slower growth this year after Wegovy sales more than doubled in the fourth quarter, with analysts and investors ...

As Novo Nordisk works through a period of transition in the U.S. GLP-1 drug market, sales from the company's star obesity medicine Wegovy came in below expectations in the first quarter of 2025.